Revenue of $666 million in the Second Quarter, down 3% Year-over-YearPrivate Cloud Revenue was $250 million, down 4% Year-over-YearPublic Cloud Revenue was $417 million, down 2% Year-over-YearSecond Quarter 2025 Cash Flow From Operating Activities was $8 million; Cash Flow From Operating Activities was $127 million on a Trailing-Twelve-Month Basis SAN ANTONIO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Rackspace Technology, Inc. (Nasdaq: RXT), a leading end-to-end, hybrid cloud and AI solutions company, today announ ...

BEACON-IPF close out activities continue Previously announced workforce and operational realignment largely complete Phase 1 oncology trial on track to deliver additional data by the end of the year SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in integrin-based drug development, today provided a corporate update and reported second quarter 2025 financial results. “While our activities in the quarter ...

/NOT FOR DISTRIBUTION TO U.S. WIRE SERVICESOR FOR DISSEMINATION IN THE U.S./ TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Urbana Corporation (TSX & CSE: URB & URB.A) is pleased to report results from its recently completed winter drill program at its 100%-owned Urban Gold Project, located approximately nine (9) kilometres southwest of the Windfall gold deposit in Quebec’s prolific Abitibi Greenstone Belt. The 5,226-metres program, comprising 17 drill holes, focused on the southern portion of the project area. ...

TUCSON, AZ, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Liberty Star Minerals (“Liberty Star” or the “Company”) (OTCQB: LBSR) is proud to highlight the renewed national focus on its flagship Hay Mountain Project in Cochise County, Arizona—a property now recognized as a cornerstone for America’s critical mineral ambitions. This builds on a surge of exploration momentum and a successful Washington, DC advocacy campaign in May led by Board Chairman Pete O’Heeron. Congressional Support: Gosar’s Letter to Cabinet Secretar ...

OAKDALE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Oak Valley Community Bank, a wholly-owned subsidiary of Oak Valley Bancorp (NASDAQ: OVLY), announced that Twyla Brooks has joined the bank as Vice President, Regional Branch Manager. She will be based out of the new Lodi Branch, located at 31 South School Street, which is slated to open this fall. Brooks brings 20 years of banking experience to her new role, including 14 years with her previous employer where she served as a VP Retail Branch Manager of thei ...

TAICHUNG CITY, Taiwan, Aug. 07, 2025 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions across a wide range of applications including personal sports equipment, healthcare products, automobile parts, resin systems, and research and development services, today announced that it closed the sale of an additional 187,500 ordinary shares of the Company, pursuant to the full exercise of the underwriters’ over-allotment op ...

Core Point - Nicolas Neuwirth has resigned from the Board of Directors of RIAS [1] Company Summary - The resignation of Nicolas Neuwirth from the board may impact the governance and strategic direction of RIAS [1]

AUGA group, RAB 2025-08-07 AUGA group, AB has published Green Bond Report In December 2019, AUGA group, RAB issued and successfully distributed its first tranche of green bonds. The Company has an obligation to publish a separate annual report regarding the use of funds. This Green Bond Report (see attachment) provides an overview on the allocation of funds raised as of December 31, 2024. Contacts: Chief Financial Officer of company under restructuring AUGA group, ABKristupas Baranauskas +370 5 233 5340 A ...

AUGA group, RAB 2025-08-07 AUGA group, RAB published Audited Results for 2024 AUGA group, RAB, code 126264360, address Konstitucijos pr. 21C, Vilnius (hereinafter – the Company), has published the Company's consolidated and separate financial statements, consolidated management report and independent auditor's report for the year ended 31 December 2024, as well as the sustainability report for the reporting period (attached). The audited revenue of the Company and its subsidiaries (hereinafter – the Group) ...

Core Insights - Dogwood Therapeutics is progressing with its Phase 2b study of Halneuron for chemotherapy-induced neuropathic pain (CINP), with interim data readout expected in Q4 2025 [1][5] - The trial has shown a low discontinuation rate of 6% due to adverse events among the first 35 patients, indicating good tolerability of both Halneuron and placebo treatments [1][4] - The company has enrolled the first 50 patients and aims to analyze data from approximately 100 patients by the end of 2025 [1][3] Company Overview - Dogwood Therapeutics is a development-stage biopharmaceutical company focused on creating new medicines for pain and fatigue-related disorders [5] - The lead product candidate, Halneuron, is a non-opioid NaV 1.7 inhibitor specifically targeting neuropathic pain associated with chemotherapy [4][5] - The company has received fast track designation from the FDA for Halneuron's treatment of CINP [4] Clinical Trial Details - The HALT-CINP trial is a randomized Phase 2b study evaluating Halneuron's safety and effectiveness against placebo in cancer patients with neuropathy from platinum or taxane-based chemotherapy [3] - Participants will receive 8 daily subcutaneous doses of Halneuron or placebo over 14 days, followed by a 28-day safety and effectiveness assessment [3] - Primary endpoints include overall safety and changes in pain intensity, while secondary measures will evaluate effects on sleep, fatigue, and overall health [3] Market Position and Future Plans - There is growing interest in sodium channel inhibition for pain treatment, with Halneuron's specificity and potency for Nav 1.7 setting it apart from other research programs [2] - Positive data from previous trials has increased interest from both patients and the research community, prompting the addition of more qualified research sites [2] - Full results from the Phase 2b trial are anticipated in mid-2026 [2]